托伐普坦用于老年急性失代偿性心力衰竭患者——一种值得考虑的治疗选择。 - Suppr

Suppr

超能文献

Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration.

作者信息

Ndrepepa Gjin

机构信息

Department of Adult Cardiology, Deutsches Herzzentrum München, Technical University; Munich-Germany.

出版信息

Anatol J Cardiol. 2017 Sep;18(3):213-214. doi: 10.14744/AnatolJCardiol.2017.8033.

DOI:10.14744/AnatolJCardiol.2017.8033

PMID:28883307

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5689053/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f87e/5689053/76ebc7d26ab9/AJC-18-213-g001.jpg

相似文献

Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration.托伐普坦用于老年急性失代偿性心力衰竭患者——一种值得考虑的治疗选择。

Anatol J Cardiol. 2017 Sep;18(3):213-214. doi: 10.14744/AnatolJCardiol.2017.8033.

Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.V2受体拮抗剂早期用于老年失代偿性心力衰竭患者的疗效与安全性

Heart Vessels. 2018 Feb;33(2):145-154. doi: 10.1007/s00380-017-1039-7. Epub 2017 Aug 16.

Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.在老年急性失代偿性心力衰竭患者中，早期给予托伐普坦可保留肾功能。

J Cardiol. 2016 May;67(5):399-405. doi: 10.1016/j.jjcc.2015.09.020. Epub 2015 Dec 11.

Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.急性失代偿性心力衰竭患者使用托伐普坦治疗的反应者的临床特征：保留肾脏大小的重要性。

J Cardiol. 2016 Feb;67(2):177-83. doi: 10.1016/j.jjcc.2015.04.017. Epub 2015 Jun 10.

Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.托伐普坦对急性失代偿性心力衰竭合并慢性肾脏病患者的临床疗效

Heart Vessels. 2016 Oct;31(10):1643-9. doi: 10.1007/s00380-015-0775-9. Epub 2015 Nov 28.

Effects of Tolvaptan With or Without the Pre-Administration of Renin-Angiotensin System Blockers in Hospitalized Patients With Acute Decompensated Heart Failure.

Int Heart J. 2017 May 31;58(3):385-392. doi: 10.1536/ihj.16-220. Epub 2017 May 8.

Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.托伐普坦早期用于高龄急性失代偿性心力衰竭患者的临床效用

Anatol J Cardiol. 2017 Sep;18(3):206-212. doi: 10.14744/AnatolJCardiol.2017.7628. Epub 2017 Aug 2.

Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.在急性失代偿性心力衰竭反复住院后的高龄患者中早期给予托伐普坦的有益效果。

Heart Vessels. 2018 Feb;33(2):163-169. doi: 10.1007/s00380-017-1048-6. Epub 2017 Sep 9.

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.伴有低钠血症和失代偿性收缩性心力衰竭患者的临床病程和用托伐普坦拮抗血管加压素受体的效果。

J Card Fail. 2013 Jun;19(6):390-7. doi: 10.1016/j.cardfail.2013.04.001. Epub 2013 May 14.

Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.托伐普坦治疗急性失代偿性心力衰竭伴肾功能衰竭患者的临床疗效：AQUAMARINE 研究的设计与原理。

Cardiovasc Drugs Ther. 2014 Feb;28(1):73-7. doi: 10.1007/s10557-013-6491-8.

引用本文的文献

Tolvaptan should be used very carefully in very elderly patients.托伐普坦在高龄患者中应极其谨慎地使用。

Anatol J Cardiol. 2018 Jan;19(1):79. doi: 10.14744/AnatolJCardiol.2017.8195.

本文引用的文献

Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.托伐普坦早期用于高龄急性失代偿性心力衰竭患者的临床效用

Anatol J Cardiol. 2017 Sep;18(3):206-212. doi: 10.14744/AnatolJCardiol.2017.7628. Epub 2017 Aug 2.

A new approach to treatment of acute heart failure.一种治疗急性心力衰竭的新方法。

J Cardiol. 2016 May;67(5):395-8. doi: 10.1016/j.jjcc.2016.02.004. Epub 2016 Mar 3.

J Cardiol. 2016 May;67(5):399-405. doi: 10.1016/j.jjcc.2015.09.020. Epub 2015 Dec 11.

Clinical profile, management, and mortality in very-elderly patients hospitalized with acute decompensated heart failure: An analysis from the ATTEND registry.急性失代偿性心力衰竭住院的高龄患者的临床特征、管理及死亡率：来自ATTEND注册研究的分析

Eur J Intern Med. 2016 Jan;27:80-5. doi: 10.1016/j.ejim.2015.08.015. Epub 2015 Sep 29.

Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.托伐普坦用于急性心力衰竭住院患者：TACTICS试验及CHF试验SECRET的原理与设计

Circ Heart Fail. 2015 Sep;8(5):997-1005. doi: 10.1161/CIRCHEARTFAILURE.115.002259.

Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).托伐普坦在老年心力衰竭患者中的有效性和不良事件。托伐普坦上市后心力衰竭监测（SMILE研究）的中期分析。

Int Heart J. 2015;56(2):137-43. doi: 10.1536/ihj.14-332. Epub 2015 Feb 23.

Diuretics and ultrafiltration in acute decompensated heart failure.利尿剂和超滤在急性失代偿性心力衰竭中的应用。

J Am Coll Cardiol. 2012 Jun 12;59(24):2145-53. doi: 10.1016/j.jacc.2011.10.910.

Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).因心力衰竭住院患者院内死亡的预测因素：来自心力衰竭住院患者启动挽救生命治疗组织项目（OPTIMIZE-HF）的见解

J Am Coll Cardiol. 2008 Jul 29;52(5):347-56. doi: 10.1016/j.jacc.2008.04.028.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.口服血管加压素拮抗剂托伐普坦对因心力衰竭住院患者的短期临床疗效：EVEREST临床状态试验

JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.血管加压素拮抗剂托伐普坦对心力衰竭加重住院患者的影响：一项随机对照试验。

JAMA. 2004 Apr 28;291(16):1963-71. doi: 10.1001/jama.291.16.1963.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验